This report highlights the importance of screening and timely diagnosis of APS in the pediatric population presenting with venous thrombosis in the backdrop of infection. antigen and self-antigens. venous thrombosis in the presence of the latter. Early initiation of treatment is vital to reduce the morbidity associated with venous thrombosis in pediatric APS. Due to the limited available data regarding pediatric APS and its management, treatment guidelines have been adapted from literature evidence of adult-onset disease. The Single Hub and Access Point for Pediatric Rheumatology in Europe (SHARE) initiative in 2017 published treatment guidelines for any child with positive aPL antibodies and evidence of venous thrombosis. Vitamin K antagonist such as warfarin was described as the primary modality of treatment of thrombosis in this population. INR was to be targeted to 3.0-4.0, and in the case of persisting aPL antibodies, long-term anticoagulation was recommended. In the case of arterial thrombosis, it was also recommended to include antiplatelet agents such as aspirin and clopidogrel alongside long-term anticoagulation [10]. Data is limited with the use of low-molecular-weight heparins, unfractionated heparin, Abiraterone (CB-7598) and newer oral anticoagulants. Another disadvantage of using heparin is the parenteral mode of drug administration, which children may not be compliant with [10]. Our patient was administered heparin initially and warfarin, which was slowly titrated to achieve the target INR of 3. During the hospital stay, he was administered anti-leprotic medications to treat the underlying leprosy and concurrently Abiraterone (CB-7598) managed with anticoagulation for the venous thrombosis. Conclusions This case highlights the rare occurrence of Abiraterone (CB-7598) pediatric APS secondary to leprosy. Leprosy, an endemic disease in certain parts of the world, must involve careful evaluation and consideration of the potential venous thrombosis secondary to APS. Timely interventions through radiological diagnostics such as Doppler scans and thrombophilia workup are warranted in such patients. Increased aPTT during the workup of these patients necessitates further workup of potential APS. Vitamin K Abiraterone (CB-7598) antagonists remain the mainstay of deep vein thrombosis in secondary pediatric APS, and larger randomized control trials are required to ascertain the use of NOACs and heparin in such patients. Notes The content published in Cureus is the result of clinical experience and/or research by independent individuals or organizations. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein. All content published within Cureus is intended only for educational, research and reference purposes. Additionally, articles published within Cureus should not be deemed a suitable substitute for the advice of a qualified health care professional. Do not disregard or avoid professional medical advice due to content published within Cureus. The authors have declared that no competing interests exist. Human Ethics Rabbit Polyclonal to ADORA2A Consent was obtained or waived by all participants in this study.